[{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio ","pharmaFlowCategory":"D","amount":"$23.8 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ 3SBio ","highestDevelopmentStatusID":"5","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Multi-specific antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Kaken","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"NM21-1480","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Numab Therapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Sunshine Guojian Pharmaceutical","pharmaFlowCategory":"D","amount":"$15.2 million","upfrontCash":"Undisclosed","newsHeadline":"Numab and 3SBio\u2019s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"ND021","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Numab Therapeutics \/ Numab Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$276.6 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Numab Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"NM26-2198","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NM26-2198","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"NM49","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$1,250.0 million","newsHeadline":"Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"NM26","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":1.25,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.25,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."}]

Find Clinical Drug Pipeline Developments & Deals by Numab Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The agreement aims to acquire NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD).

                          Product Name : NM26-2198

                          Product Type : Large molecule

                          Upfront Cash : $1,250.0 million

                          May 28, 2024

                          Lead Product(s) : NM26

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Johnson & Johnson

                          Deal Size : $1,250.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Through collaboration, Ono has obtained rights for NM49 from Numab for global development and commercialization, which is a multi-specific antibody designed to activate tumor-associated macrophage phagocy...

                          Product Name : NM49

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 14, 2024

                          Lead Product(s) : NM49

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : NM26/NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). MAD data expected to be reported in mid-2024; Single ascending dose (SAD) cohort in he...

                          Product Name : NM26

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 19, 2023

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).

                          Product Name : NM26-2198

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 15, 2023

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Kaken Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-onco...

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : Antibody

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Partner/Sponsor/Collaborator : Ono Pharmaceutical

                          Deal Size : $276.6 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules including ND021, emerging from the three multispecific antibody programs based on Numab’s R&D platform and has...

                          Product Name : ND021

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 14, 2021

                          Lead Product(s) : ND021

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Sunshine Guojian Pharmaceutical

                          Deal Size : $15.2 million

                          Deal Type : Partnership

                          blank

                          07

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : NM21-1480

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Partner/Sponsor/Collaborator : Novo Holdings

                          Deal Size : $110.0 million

                          Deal Type : Series C Financing

                          Details : Proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-...

                          Product Name : NM21-1480

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 20, 2021

                          Lead Product(s) : NM21-1480

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Partner/Sponsor/Collaborator : Novo Holdings

                          Deal Size : $110.0 million

                          Deal Type : Series C Financing

                          blank

                          08

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, an...

                          Product Name : NM26-2198

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 13, 2021

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Partner/Sponsor/Collaborator : Kaken Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic a...

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 07, 2020

                          Lead Product(s) : Multi-specific antibody

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 09, 2020

                          Lead Product(s) : ND021

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Partner/Sponsor/Collaborator : 3SBio

                          Deal Size : $23.8 million

                          Deal Type : Series B Financing

                          blank